需要持续肾脏替代治疗的危重儿科肿瘤与造血干细胞移植患者的流行病学与结局:一项全国性回顾性队列研究
该研究为荷兰全国性、多中心、回顾性观察性研究,纳入2006年1月至2017年7月8个三级医院PICU中接受持续肾脏替代治疗的儿科肿瘤与造血干细胞移植患者。在1,927例次PICU收治中,70例可评估患者中的68例被纳入分析。需要持续肾脏替代治疗的患者PICU死亡率为54.4%(37/68),而总体粗PICU死亡率为11.2%(216/1,972例次)。启动持续肾脏替代治疗时液体过负荷(OR 1.08;95%CI 1.01-1.17)和需要正性肌力药物支持(OR 6.53;95%CI 1.86-23.08)与PICU死亡相关。血清肌酐在启动持续肾脏替代治疗前3天升至基线150%以上,尿量未达少尿临界值,而体重(液体过负荷)在启动前5天即已增加。作者认为常用急性肾损伤标准(血清肌酐和尿量)不适合作为启动持续肾脏替代治疗的触发指标,亟需前瞻性研究以生成早期有效治疗干预的建议。
要点
- 需要持续肾脏替代治疗的儿科肿瘤与造血干细胞移植患者PICU死亡率为54.4%(37/68),总体粗PICU死亡率为11.2%(216/1,972例次)。
- 启动持续肾脏替代治疗时液体过负荷与PICU死亡相关(OR 1.08;95%CI 1.01-1.17),是需要正性肌力药物支持(OR 6.53;95%CI 1.86-23.08)之外的重要预测因素。
- 体重(液体过负荷)在启动持续肾脏替代治疗前5天即已增加,而血清肌酐在启动前3天升至基线150%以上,尿量未达少尿临界值。
- 作者认为常用急性肾损伤标准(血清肌酐和尿量)不适合作为启动持续肾脏替代治疗的触发指标。
- 作者指出亟需前瞻性研究以生成该特定人群早期有效治疗干预的建议。
适用人群与场景
- 荷兰8个三级医院PICU中收治的儿科肿瘤与造血干细胞移植患者(癌症和非癌症),在2006年1月至2017年7月期间接受持续肾脏替代治疗者。
- 研究纳入70例可评估患者中的68例接受持续肾脏替代治疗者进行分析。
研究设计与关键结果
- 研究类型为全国性、多中心、回顾性、观察性研究,纳入荷兰8个三级医院PICU的68例接受持续肾脏替代治疗的儿科肿瘤与造血干细胞移植患者。
- 在1,927例次PICU收治中,总体粗PICU死亡率为11.2%(216/1,972例次);需要持续肾脏替代治疗的患者PICU死亡率为54.4%(37/68)。
- 启动持续肾脏替代治疗时液体过负荷与PICU死亡相关(OR 1.08;95%CI 1.01-1.17),需要正性肌力药物支持与PICU死亡相关(OR 6.53;95%CI 1.86-23.08)。
- 血清肌酐在启动持续肾脏替代治疗前3天升至基线150%以上,尿量未达少尿临界值,而体重(液体过负荷)在启动前5天即已增加。
证据类型、等级与局限
- 证据类型:全国性、多中心、回顾性、观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,最常用的急性肾损伤标准(即血清肌酐和尿量)不适合作为启动持续肾脏替代治疗的触发指标。
- 作者指出,亟需前瞻性研究以生成该特定患者人群早期有效治疗干预的建议。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Acute kidney injury requiring continuous renal replacement therapy is a serious treatment-related complication in pediatric cancer and hematopoietic stem cell transplant patients. The purpose of this study was to assess epidemiology and outcome of these patients requiring continuous renal replacement therapy in the PICU.
DESIGN: A nationwide, multicenter, retrospective, observational study.
SETTING: Eight PICUs of a tertiary care hospitals in the Netherlands.
PATIENTS: Pediatric cancer and hematopoietic stem cell transplant patients (cancer and noncancer) who received continuous renal replacement therapy from January 2006 to July 2017 in the Netherlands.
INTERVENTIONS: None.
MEASUREMENT AND MAIN RESULTS: Of 1,927 PICU admissions of pediatric cancer and hematopoietic stem cell transplant patients, 68 of 70 evaluable patients who received continuous renal replacement therapy were included. Raw PICU mortality was 11.2% (216/1,972 admissions). PICU mortality of patients requiring continuous renal replacement therapy was 54.4% (37/68 patients). Fluid overload (odds ratio, 1.08; 95% CI, 1.01-1.17) and need for inotropic support (odds ratio, 6.53; 95% CI, 1.86-23.08) at the start of continuous renal replacement therapy were associated with PICU mortality. Serum creatinine levels increased above 150% of baseline 3 days before the start of continuous renal replacement therapy. Urine production did not reach the critical limit of oliguria. In contrast, body weight (fluid overload) increased already 5 days prior to continuous renal replacement therapy initiation.
CONCLUSIONS: PICU mortality of pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal replacement therapy is sadly high. Fluid overload at the initiation of continuous renal replacement therapy is the most important and earliest predictor of PICU mortality. Our results suggest that the most commonly used criteria of acute kidney injury, that is, serum creatinine and urine production, are not useful as a trigger to initiate continuous renal replacement therapy. This highlights the urgent need for prospective studies to generate recommendations for effective therapeutic interventions at an early phase in this specific patient population.
参考来源
- Raymakers-Janssen PAMA, Lilien MR, Tibboel D, et al. Epidemiology and Outcome of Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients Requiring Continuous Renal Replacement Therapy: A Retrospective Nationwide Cohort Study. Crit Care Med. 2019. PMID: 31464768. doi:10.1097/CCM.0000000000003973
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。